Welltica+ on MSN

Tiny implant eliminates bladder cancer in 82% of patients

A new slow-release implant has shown unprecedented success in wiping out bladder cancer in more than 80 percent of patients, ...
Nasdaq

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...
Science Daily

Tiny implant wipes out bladder cancer in 82% of patients

TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...
Open Access Government

Tiny bladder implant, TAR-200, eliminates cancer in 82% of patients

The TAR‑200 slow‑release bladder implant cleared tumours in 82% of patients with high‑risk non‑muscle‑invasive bladder cancer ...